Professor Max C (@ProfCMaxi) - Twitter-Profil | Zamantika Mersobahis Locabet

Professor Max C retweetet

Antonio Linares@alc2022·15h

I went long $AMD at $4.2 a decade ago. Chiplets were going to be the foundation of modern compute. I was right. $IBRX feels the same way now but in biotech. $IBRX Anktiva is not just a fusion protein complex. It is an OS for the human immune system.

Dr. Pat Soon-Shiong@DrPatrick

Global expansion-first approval in Asia!! Anktiva now approved in Macau, China today. Paradigm change of treating the immune system unstoppable.

English

19

43

438

79.6K

Professor Max C retweetet

Dr. Pat Soon-Shiong@DrPatrick·18h

Global expansion-first approval in Asia!! Anktiva now approved in Macau, China today. Paradigm change of treating the immune system unstoppable.

English

72

188

1.1K

119.3K

Professor Max C@ProfCMaxi·18h

@DrPatrick $IBRX is on a roll! Congratulations and thank you and your team for your efforts!

English

0

1

22

917

Professor Max C retweetet

Dr. Pat Soon-Shiong@DrPatrick·18h

Great announcement today by HHS and NCI to support cancer vaccine trials. We have spent the past decade collaborating with 2 amazing thought leaders at the National Cancer Institute (NCI) in the field of cancer vaccine, Dr James Gulley and Dr Jeffrey Schlom. Together we have completed Phase 1 & 2 trials across multiple tumor types showing how our Adeno vaccine plus Anktiva generates tumor specific T cells. The randomized trial to PREVENT cancer in subjects with Lynch Syndrome which affects over a million Americans (1 in 278) is fully enrolled and the early data so far shows that Anktiva and the Adeno vaccine increases NK and T cells in these subjects, even in subjects aged 65 wsj.com/articles/hhs-h…

English

30

172

797

51.4K

Professor Max C retweetet

Tiger Line Trading@TigerLineTrades·21h

$IBRX BREAKING 4HR HIGH!!

English

0

3

8

1.7K

Professor Max C@ProfCMaxi·1d

$IBRX is changing cancer care. This is what a platform company in the making looks like, and it's just getting started.

Dr. Pat Soon-Shiong@DrPatrick

Just received amazingly exciting analysis of the first 20 subjects without cancer but with Lynch Syndrome ( now fully enrolled with 138 randomized to either Anktiva plus our Adeno CANCER VACCINE versus placebo). This first set of biological immune data from NCI ( Dr Jeff Schlom) and his team is so exciting and confirms the immune stimulating effect of Anktiva re ALC. Also it shows that as we age the baseline ALC is low but Anktiva changes that level..really exciting especially in light of the JAMA paper that shows 1 in 5 Americans suffer from lymphopenia and that with a low ALC this results in a significant lower lifespan. More to come! The cancer vaccine trials are underway!

English

2

7

76

2.8K

Professor Max C@ProfCMaxi·1d

@DrPatrick Amazing work, congratulations to you and the team! $IBRX

English

0

14

1.2K

Dr. Pat Soon-Shiong@DrPatrick·1d

Just received amazingly exciting analysis of the first 20 subjects without cancer but with Lynch Syndrome ( now fully enrolled with 138 randomized to either Anktiva plus our Adeno CANCER VACCINE versus placebo). This first set of biological immune data from NCI ( Dr Jeff Schlom) and his team is so exciting and confirms the immune stimulating effect of Anktiva re ALC. Also it shows that as we age the baseline ALC is low but Anktiva changes that level..really exciting especially in light of the JAMA paper that shows 1 in 5 Americans suffer from lymphopenia and that with a low ALC this results in a significant lower lifespan. More to come! The cancer vaccine trials are underway!

English

76

236

1.4K

76.4K

Professor Max C retweetet

Lori Mills@LoriMills4CA42·1d

@SecKennedy @DrOzCMS How about you just cut the red tape on #ANKTIVA and NK cell therapy for all cancer patients?

English

3

4

36

677

Professor Max C@ProfCMaxi·1d

@bullishbruk What are you seeing?

English

0

2

532

Bullish@bullishbruk·1d

$IBRX I don’t know if it is a trick or what but, some shorts started covering sloooowwwly……

English

6

3

92

4.5K

Professor Max C@ProfCMaxi·1d

Long $IBRX!

Bullish@bullishbruk

$IBRX – Even though mainland China hasn’t approved ANKTIVA for bladder cancer yet, Macau is fast-tracking access by leveraging the existing U.S. and EU approvals. The drug is now available locally much quicker, and yes — ANKTIVA is actively expanding across Asia. @DrPatrick @LoriMills4CA42

English

0

2

37

1.4K

Professor Max C@ProfCMaxi·2d

@DrMakaryFDA #ANKTIVA next!?

English

0

16

89

Dr. Marty Makary@DrMakaryFDA·2d

Some FDA decisions are taking WEEKS. Thank you to the dedicated FDA scientists who are making this unprecedented efficiency possible.

English

125

51

450

53.1K

Professor Max C retweetet

Dr. Pat Soon-Shiong@DrPatrick·2d

Pleased with the NCCN guidelines for Papillary only disease in non-muscle invasive bladder cancer (NMIBC). Validates the publication in Journal of Urology. Now next step is to provide BCG for all patients who could benefit in bladder cancer. pubmed.ncbi.nlm.nih.gov/40956664/

English

33

100

529

22.9K

Professor Max C@ProfCMaxi·2d

RT @ImmunityBio: Progress in non-muscle invasive bladder cancer (NMIBC) care is driven by a deeper understanding of the disease and a commi…

English

0

2

0

16

Professor Max C retweetet

The Trend Sage - Jonkoo@JonkooTrades·3d

$IBRX - ImmunityBio Price Target Maintained With a $23.00/Share by D. Boral Capital

English

1

8

74

2.2K

Professor Max C retweetet

ImmunityBio, Inc.@ImmunityBio·3d

The NCCN® Clinical Practice Guidelines now include ANKTIVA® plus BCG for patients with BCG-unresponsive NMIBC with papillary-only disease. This update reflects continued progress in expanding treatment considerations for patients facing limited options following BCG therapy. Learn more: immunitybio.com/immunitybio-an…

English

0

65

357

21.6K

Professor Max C@ProfCMaxi·3d

@TigerLineTrades Long $IBRX ir.immunitybio.com/news-releases/…

English

1

0

4

161

Tiger Line Trading@TigerLineTrades·3d

$IBRX VOLUME COMING IN...

English

1

14

1.4K

Professor Max C retweetet

𝒰𝓂𝒷𝒾𝓈𝒶𝓂@Umbisam·3d

$IBRX I agree with Bullish, this is very relevant. ANKTIVA is now recommended by urologists/oncologists even for papillary-only treatments. Meaningfully expanding potential beneficiaries (~2.2x), leading to insurance coverage & Medicare reimbursements. More details here.